CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. - Wikidata - awgldk - TriplyDB

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

http://www.wikidata.org/entity/Q34585720

about

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response Foxp3+ regulatory T cells are required for recovery from severe sepsis Harnessing the Microbiome to Enhance Cancer Immunotherapy Orchestration of angiogenesis by immune cells Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis The Relationship between Obesity, Prostate Tumor Infiltrating Lymphocytes and Macrophages, and Biochemical Failure Prostate cancer and inflammation: the evidence.A different representation of natural T cells and natural killer cells between tumor-infiltrating and periphery lymphocytes in human hepatocellular carcinoma.Transcriptional regulation of FOXP3 requires integrated activation of both promoter and CNS regions in tumor-induced CD8+ Treg cells.Exacerbation of corneal scarring in HSV-1 gK-immunized mice correlates with elevation of CD8+CD25+ T cells in corneas of ocularly infected mice.CD8+ Tregs in lupus, autoimmunity, and beyond.The future potential for cocaine vaccines.Osteoclast activated FoxP3+ CD8+ T-cells suppress bone resorption in vitro.The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.Prostate cancer as a model for tumour immunotherapy.TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence.Augmenting antitumor immune responses with epigenetic modifying agents.Direct Toll-Like Receptor 8 signaling increases the functional avidity of human CD8+ T lymphocytes generated for adoptive T cell therapy strategies.Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma.The PCa Tumor Microenvironment.Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells Prostate cancer immunotherapy.A Bone Anabolic Effect of RANKL in a Murine Model of Osteoporosis Mediated Through FoxP3+ CD8 T Cells.Interleukin-35 administration counteracts established murine type 1 diabetes--possible involvement of regulatory T cells.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD.CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity.Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment.Differential patterns of large tumor antigen-specific immune responsiveness in patients with BK polyomavirus-positive prostate cancer or benign prostatic hyperplasia Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy.Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells.Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence

P2860

Q26740601-2EBC0618-FC0D-4EDF-B8F3-A5941443B5D8 Q26744527-FCF932A1-3010-43A8-B5E9-D90ACC4BFEA6 Q27317316-68FB101B-8F70-4E05-825B-8393FFD29F99 Q28088598-2FB94A1A-9272-41D7-8353-DA74418D7BF7 Q28389236-66E3416E-B763-455C-8D8A-471504EAFDAE Q28552296-4537BE2E-A815-4484-9961-9BC2379E8A89 Q28553364-BDDDC163-15F1-4A62-B595-0D9088BE85DB Q33642321-26F74778-0C39-42DB-AB1D-2C802BB36EAA Q33685646-B8B5B163-6733-4115-86D6-13FA2878DC1D Q33686415-7ABA0070-E0B5-4F04-83DB-ACF9862E52FD Q33695351-86F39DBB-951D-4551-B281-E177A038FB24 Q33889097-B2325B46-A292-4599-91EF-1867755C6E3E Q34132804-9DB6205E-A061-43EC-9974-8F1CFC0E3BE2 Q34305347-FB5466BA-4AE9-415A-8A52-710A1A127C5E Q34315871-E00741B6-3191-4B70-898F-DB4956422FCC Q34478019-89CBEDFF-D6E5-47E2-AD35-00AAA2131CD9 Q34612943-74F666D5-B8D3-44FB-9E86-39A7F107FEBF Q34645401-A1F16C2C-0831-4444-AF84-217FFB8DEF67 Q34725101-F271A0DE-6FAB-4017-9F7E-D40A51334A94 Q34856875-58544B6B-DF2D-4E9B-8B1F-63F232CEFAE3 Q34880391-46EB78BF-ECC8-4F31-A0DC-416B5226D90B Q35048054-C5469B45-05FB-4AAB-8373-8AA550595E9C Q35285757-157713BA-B01A-4A8C-84AB-17ECDF11DD55 Q35426986-6D34D8CD-7316-4F54-A81C-FC1A4ADACED8 Q35567212-184A13D9-A5F9-4793-8DD3-5C3317247E93 Q35570420-8E5E15F8-CC80-4542-AA73-709C072702C4 Q35603143-9F08DEB6-F2A7-45B9-A836-5A9647A05EF7 Q35644193-83F6E911-3E9B-4831-B0DB-953178C37F49 Q35688425-978C0DA8-3638-4FB7-9B3D-B10B611A866D Q35864012-C022D437-9F4F-415E-AC76-0DA55E9F0A78 Q35902052-4FB767EE-7E7D-4994-AE7C-DDB6B42FE751 Q35980893-739CA56F-8733-4748-A656-CDDC2CF15BE5 Q36015241-ECDC91A0-4B7F-4080-BF5B-C74BCD73B18F Q36055096-1F8D604F-D3C8-4C4E-8B3B-E1F2A5AE5EE5 Q36085104-92923091-7B7C-4622-96E4-4A4DD66BCDF1 Q36172036-7CDDA1CF-E5C6-4892-A724-069F289563F6 Q36413093-57AA21FC-63B6-4895-9B13-225420C93DC1 Q36456469-B2091207-9757-452B-83C0-033E63527C7D Q36602010-B528878F-89A9-40EA-8194-5107094AFEBA Q36625669-8C9CDDCB-94AB-42C0-8F49-1515BCD6399B

P2860

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

http://www.wikidata.org/entity/Q34585720

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

@ast

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

@en

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

@nl

type

label

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

@ast

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

@en

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

@nl

prefLabel

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

@ast

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

@en

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

@nl

P1433

Q34585720-71B67E66-DA12-4338-9C59-646111D35679

P1476

Q34585720-FD1104FB-766E-4B0A-B482-C68FB8B83431

P2093

Q34585720-0B6D5BEC-AF00-4E15-95FF-B0CD968E169C

Q34585720-1A93C1AE-CD60-457E-93DF-775A4276948B

Q34585720-3092FDFE-44CB-4F5F-AA8B-D254722161A0

Q34585720-3B7927E6-35AB-4E82-870B-655B1CF60E72

Q34585720-3EC12E38-10E2-4DFD-AEF6-35F3C1D9B83B

Q34585720-5B2ADFE1-F78F-4F8B-A865-E52B22D1009B

Q34585720-9AB9B4B6-BA57-4E7C-ABF8-166D15B52984

Q34585720-C1B787E5-FE40-42F6-A509-8DFF71248835

Q34585720-D570FF58-6FB9-4FD7-B923-E7C4C0733E8C

P304

Q34585720-9C623C84-3570-4DE7-8D0A-B33477ACB4E0

P31

Q34585720-9E884A6E-9A79-44D5-850E-224C18E55A35

P356

Q34585720-BDBA6427-2861-4528-9C5D-0E73B5DE5438

P407

Q34585720-FB357EC3-F3CC-4165-AB4A-DCA07E07CE62

P433

Q34585720-33EA0841-3433-4129-B1F0-0F8D229F3177

P478

Q34585720-A1B2347B-D70D-41B7-AEDF-68C12EA80F9B

P577

Q34585720-8CB5A101-0D3C-4253-8CC2-8F8C081BBA63

P698

Q34585720-2166C520-046B-4E58-B7BE-B11FB8F0E8FD

P921

Q34585720-B928810D-A058-4CC7-8139-533C7B53F901

P356

1078-0432.CCR-07-0842

P1433

Clinical Cancer Research

P1476

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.

@en

P2093

Guangyong Peng

http://www.w3.org/2001/XMLSchema#string

Helen Y Wang

http://www.w3.org/2001/XMLSchema#string

Lloyd J Old

http://www.w3.org/2001/XMLSchema#string

Rong-Fu Wang

http://www.w3.org/2001/XMLSchema#string

Thomas M Wheeler

http://www.w3.org/2001/XMLSchema#string

Timothy C Thompson

http://www.w3.org/2001/XMLSchema#string

Weiyi Peng

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Miyahara

http://www.w3.org/2001/XMLSchema#string

Yukiko Kiniwa

http://www.w3.org/2001/XMLSchema#string

P304

6947-6958

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-07-0842

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18056169

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression